Sweden Pharmaceuticals & Healthcare Report Q3 2013
Published by Business Monitor International
on May 21, 2013
, 98 pages
PDF - Download Now with 3 Quarterly Updates format - Delivered by download
BMI View: While we expect that the Swedish pharmaceutical market will decline in coming years, under pressure from generic medicines, patent expirations and a general climate of cost containment, we remain optimistic about the country's long-term attractiveness. This view covers both consumption (which is supported by well-developed public financing and healthcare systems) and research and development (R&D) initiatives in the country, with global pharmaceutical major AstraZeneca recently confirming its commitment to local R&D activities.